De Groot, S <br/><br/>
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.  [electronic resource] 

 -  PloS one  2017 
 - e0177364 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0177364  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--economics<br/>Carcinoma, Renal Cell--drug therapy<br/>Cost of Illness<br/>Cost-Benefit Analysis<br/>Female<br/>Humans<br/>Indoles--economics<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Netherlands<br/>Pyrroles--economics<br/>Quality-Adjusted Life Years<br/>Registries<br/>Regression Analysis<br/>Sunitinib<br/>Treatment Outcome<br/>Young Adult